Analysts expect Mylan NV (NASDAQ:MYL) to report sales of $2.84 billion for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Mylan’s earnings, with the highest sales estimate coming in at $2.90 billion and the lowest estimate coming in at $2.75 billion. Mylan reported sales of $2.81 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 1.1%. The firm is expected to report its next quarterly earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Mylan will report full year sales of $11.69 billion for the current fiscal year, with estimates ranging from $11.50 billion to $11.87 billion. For the next financial year, analysts expect that the company will post sales of $12.17 billion, with estimates ranging from $11.78 billion to $12.79 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Mylan.
Mylan (NASDAQ:MYL) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.03. The company had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.70 billion. Mylan had a net margin of 2.14% and a return on equity of 18.96%. Mylan’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.96 EPS.
NASDAQ:MYL traded up $0.25 on Friday, hitting $19.67. The company had a trading volume of 7,061,903 shares, compared to its average volume of 6,233,676. The company has a market cap of $10.12 billion, a price-to-earnings ratio of 4.29, a PEG ratio of 1.02 and a beta of 1.44. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.51 and a quick ratio of 0.85. Mylan has a 52 week low of $19.14 and a 52 week high of $42.50.
In other news, insider Paul Campbell sold 11,533 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $27.50, for a total transaction of $317,157.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.81% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of MYL. Global Retirement Partners LLC lifted its position in Mylan by 107.1% in the first quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock worth $27,000 after buying an additional 500 shares during the last quarter. Pinnacle Bank lifted its position in Mylan by 66.4% in the 1st quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock valued at $30,000 after acquiring an additional 423 shares in the last quarter. Cresset Asset Management LLC bought a new stake in Mylan in the 1st quarter valued at $41,000. Mascoma Wealth Management LLC bought a new stake in Mylan in the 1st quarter valued at $47,000. Finally, Kinneret Advisory LLC bought a new stake in Mylan in the 4th quarter valued at $71,000. Institutional investors own 83.69% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
See Also: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.